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This study examined whether secondary medical diagnoses
that affect CNS function (i.e., seizures, malformations, or
genetic disorders), are more likely to occur in individuals
with fragile X syndrome (FXS) and autism spectrum disorder
(FXSþASD) or FXS alone. Ninety males (3–25 years) with
FXS or FXSþASD were evaluated for secondary medical
diagnoses by medical history and examination. A significant
difference in the incidence of medical problems was found
between patients with FXSþASD (38.6%) and FXS alone
(18.2%, P< 0.05). Medical problems that affect the CNS are
more likely to occur in those with FXSþASD and it is
probable that additional brain dysfunction associated with
these medical problems enhance the risk of autism in those
with FXS.  2008 Wiley-Liss, Inc.
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INTRODUCTION
Fragile X syndrome (FXS) is the most common
inherited cause of mental retardation, affecting
an estimated 1 in 3,600 males in the general popula-
tion [Sherman, 2002]. The phenotype of FXS includes
intellectual disability, cognitive and behavioral im-
pairments of varying degree, and physical anomalies
such as large ears, long face, macrocephaly, and
macroorchidism [Lachiewicz et al., 2000; Hagerman,
2002]. Behavior characteristics frequently reported
include social avoidance, anxiety, poor eye contact,
perseverative behavior, hyperarousal to sensory
stimuli, distractibility, irritability, hyperactivity, repeti-
tive motor behaviors, and inflexibility [Hagerman,
2002; Artigas and Brun, 2004; Hatton et al., 2006].
FXS is caused by an unstable mutation in the fragile
X mental retardation 1 (FMR1) gene. Expansion of a
trinucleotide (CGG) repeat (>200) in the 50 untrans-
lated region of the gene leads to gene silencing and a
lack or deficiency of the FMR1 protein (FMRP),
which causes thephysical, cognitive, behavioral, and
emotional characteristics of FXS [Tassone et al.,
1999]. Normal individuals have 5–44 CGG repeats
that are stably transmitted to the next generation.
Alleles harboring 45–54 CGG repeats are named
‘‘gray zone’’ because instability in transmission to
the next generation is common [Nolin et al., 1996].
With CGG repeat sizes in the premutation range (55–
200 repeats), the allele usually expands to the full
mutation (>200 repeats) when passed from a mother
to her children. A mixed pattern of full mutation and
premutation alleles is termed mosaicism.
The association between autism and FXS was first
reported in 1982 [Brown et al., 1982] and is one of the
most recognized behavioral abnormalities observed
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in males and some females with FXS. Two to six
percent of children with autism will have the FMR1
mutation [Wassink et al., 2001; Estecio et al., 2002;
Reddy, 2005] and approximately 30% of children
with FXS are diagnosed with autism [Bailey et al.,
2001a; Rogers et al., 2001; Kaufmann et al., 2004].
An additional 20–30% of patients with FXS have
Pervasive Developmental Disorder—Not Otherwise
Specified (PDDNOS) [Harris et al., 2008]. Studies
have shown that the presence of autism with FXS
is associated with language and social deficits in
addition to a lower IQ compared to childrenwith FXS
without autism [Bailey et al., 2001a; Kaufmann
et al., 2004; Philofsky et al., 2004]. IQ has also been
documented to decline with age in most males with
FXS [Wright-Talamante et al., 1996]. A decline is also
seen in individuals with Down syndrome who
develop Alzheimer disease with age [Kittler et al.,
2004], but not in the typical population [Zigler et al.,
1984].
The autism that occurs in FXS has been hypo-
thesized tobe related to a secondary genetic problem
because the degree of FMRP deficit does not
correlate with the presence of autism when IQ is
controlled [Rogers et al., 2001; Loesch et al., 2007].
Some individuals with FXS have a recognizable
second genetic abnormality or an additional medical
diagnosis, such as epilepsy, that is a known cause of
CNS dysfunction. We hypothesize that individuals
with FXS and autism will have a higher number
of secondary medical diagnoses including genetic
disorders that affect the CNS compared to those with
FXS alone. A retrospective analysis was conducted to
determine if the prevalence of secondary medical
diagnoses is different in individuals with FXS
and autism spectrum disorder (ASD, including




Included in this retrospective analysis and chart
review were 90 male participants with FXS, ages
3–25 years, who were seen sequentially at the
University of California at Davis M.I.N.D. Institute
and had an Autism Diagnostic Observation
Schedule—General [ADOS-G, Lord et al., 2000] as
part of the evaluation between January 2001 and July
2005. Subjects and parents/caregivers signed an IRB
approved consent form. All the participants had
either a full mutation or mosaicism by FMR1 DNA
testing. Each individual was evaluated for autism
or PDDNOS using the ADOS-G and the Diagnostic
StatisticalManual—Fourth Edition criteria for Autistic
Disorder [DSM-IV, APA, 1994]. Individuals who met
the criteria for autism or PDDNOS were considered
in the FXSþASD group. There were 57 individuals
with FXSþASD and 33 individuals with FXS alone.
All participantswere evaluated formedical or genetic
problems through a medical history and a detailed
examination for minor anomalies by a develop-
mental and behavioral pediatrician with expertise in
genetic disorders and fragile X syndrome (RJH).
If asymmetries were seen on neurological examina-
tion, an MRI was done. A description of the
participants is presented in Table I.
Measures
All patients completed the ADOS-G [Lord
et al., 2000] and were evaluated using the DSM-IV
criteria for Autistic Disorder [APA, 1994]. When
disagreements occurred between the two measures
a consensus was reached by a team conference
including a developmental and behavioral pedia-
trician, psychologist, social worker, and genetic
associate, who are all experienced in the diagnosis
of autism. Patients also underwent one of the
following cognitive evaluations (n¼ 64); Wechsler
Intelligence Scale for Children—3rd Edition [WISC-
III, Wechsler, 1991], Wechsler Intelligence Scale
for Children—4th Edition [WISC-IV, Wechsler,
2003], Wechsler Adult Intelligence Scale—3rd
Edition [WAIS-III, Wechsler, 1997], Wechsler Pre-
school and Primary Scale of Intelligence—3rd
Edition [WPPSI-III,Wechsler, 2002],WechslerAbbre-
viated Scale of Intelligence [WASI, Wechsler, 1999],
Stanford-Binet—4th Edition [Thorndike et al., 1986],
and Leiter International Scale of Intelligence-Revised
[Leiter-R, Roid and Miller, 1997]. In addition, the
parent/caregiver of the patients (n¼ 62) were
administered the Vineland Adaptive Behavior Scales,
Interview Edition [VABS, Sparrow et al., 1984] to
assess adaptive functioning.
The assessment of the medical and genetic con-
ditions consisted of a clinical history, a review of
medical and psychological records including neuro-
imaging and previous genetic testing, and a medical
and neurological examination previously described
in Riddle et al. [1998]. Cytogenetic testing was not
routinely completed, but was often included in the
medical records. FMR1 DNA testing was performed
on all patients. DNA testing was performed on DNA
isolated from peripheral blood leucocytes using
both Southern Blot and PCR analysis. Details of the
methods are previously described in Tassone et al.
TABLE I. Description of Participants
FXS alone (n¼ 33) FXSþASD (n¼ 57)
M SD M SD
Age (years) 7.75 3.74 9.80 5.74
FSIQ score* 61.00a 14.87 52.22b 11.54
Vineland score** 52.96c 15.14 41.79d 14.79
an¼ 28, bn¼ 36, cn¼ 24, dn¼ 38, *P< 0.05, **P< 0.01.
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[2004] and Saluto et al. [2005]. If the Prader–Willi
phenotype in FXS was present (obesity, hyper-
phagia, and small genitalia), cytoplasmic interacting
FMR1 protein (CYFIP) expression, which is found to
be lowered and associated with a higher rate of
ASD in this subgroup of FXS, was documented as
described in Nowicki et al. [2007].
RESULTS
Autism and PDDNOS
Of the 90 males, 57 (63.3%) met the criteria for ASD
according to the ADOS-G and the DSM-IV criteria for
Autistic Disorder. Twenty-nine (32%) subjects had
autism and 28 (31%) had PDDNOS. The remaining
33 (37%) did not meet criteria for ASD. Those with
autism and PDDNOS clinically are on a continuum
and since many of the individuals scored at or just
below the cut-off for autism; they were combined
in our analysis. Often in studies of autism, these
two groups are combined into the ASDs category
[Harris et al., 2008]. These percentages are quite
consistent with our overall numbers for FXSþASD.
In addition, there were no significant differences
between the FXS and PDDNOS (FXSþPDDNOS)
and FXS and autism (FXSþ autism) groups in IQ
(P¼ 0.92), VABS score (P¼ 0.06), and age (P¼ 0.83).
Combining these groups enhanced statistical power
for comparison across those with ASD and those
without.
If we compare the presence of secondary medical
diagnoses between the FXS and autism group
(FXSþ autism) and FXS and PDDNOS (FXSþ
PDDNOS) group we saw that in the FXSþPDDNOS
PDDNOS group, 11 (39.3%) had secondary medical
diagnoses and in the FXSþ autism group, 11 (37.9%)
had secondary medical diagnoses. Systematic com-
parisons between the two groups, FXSþPDDNOS
and FXSþ autism, showed no significant difference
(Chi square¼ 0.011, df¼ 1, P¼ 0.916). The presence
of secondary medical diagnoses does not dif-
ferentiate the FXSþPDDNOS from the FXSþ autism
autism group. Therefore, we combined the group
into FXSþASD for further analysis (Table II).
Mosaic and Full Mutation (FXS)
In the 90 males with FXS that were reviewed,
56 (62.2%) had the full mutation and 34 (37.8%) were
mosaic. In the group with FXSþASD (n¼ 57),
37 (64.9%) subjects had the full mutation and 20
(35.1%) subjects were mosaic. In the group with FXS
alone (n¼ 33), 19 (57.6%) subjects had the full
mutation and 14 (42.4%) subjects were mosaic
(Table II). There was no significant difference
between the two groups regarding the frequency of
the full mutation (P¼ 0.14, Table II) or mosaicism
(P¼ 0.18, Table II).
The mean age was 9.80 years (SD¼ 5.74) in the
FXSþASD group (n¼ 57) and 7.75 years (SD¼ 3.74)
in the FXS alone group (n¼ 33). There was no
significant difference between the two groups in
chronological age (P¼ 0.07, Table I).
Cognitive Ability
In assessing the cognitive ability, 64 individuals
completed the WISC-III, WISC-IV, WPPSI-III, WASI,
WAIS-III, Stanford Binet 4th Edition, or Leiter-R. The
FXSþASD group (n¼ 36) had a mean IQ score of
52.22 (SD¼ 11.54) and the FXS alone group (n¼ 28)
hadamean IQscoreof 61.00 (SD¼ 14.87). Therewas
a significant group difference in IQ (P¼ 0.013,
Table I), which has been seen in other studies
[Rogers et al., 2001; Bailey et al., 2001b; Kaufmann
et al., 2004]. The VABS was completed with a parent/
caregiver in 62 of the individuals. Thirty-eight
participants from the FXSþASD group had a VABS
mean composite score of 41.79 (SD¼ 14.79) and
24 individuals from the FXS alone group had a VABS
mean composite score of 52.96 (SD¼ 15.14). There
was a significant difference in the adaptive behavior
composite score on the VABS (P¼ 0.006, Table I),
which has been previously reported by Rogers et al.
[2001].
CNS Associated Medical Disorders
Twenty-eight (31.1%) of the 90 subjects were
found to have an associated medical disorder that
TABLE II. Medical/Genetic Results of the Two Groups (FXS Alone and FXSþASD)
FXS alone (n¼ 33) FXSþASD (n¼ 57)
Chi-square
test (P-value)n Percentage n Percentage
Full mutation 19 57.6 37 64.9 0.14
Mosaic 14 42.4 20 35.1 0.18
No medical problems 27 81.8 35 61.4 0.04
Seizures 4 12.1 16 28.1 0.15
MRI abnormalities 1 3.0 2 3.5 0.90
Genetic abnormalities 1 3.1 4 7.0 0.43
Total medical problems 6 18.2 22 38.6 0.04
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affects the CNS after a detailed medical history,
clinical exam, and further testing of a subgroup.
Twenty of the subjects had seizures; three had MRI
abnormalities, that is, white matter disease, cystic
abnormalities, and optic atrophy with microcephaly;
and five had genetic abnormalities, four with
Prader–Willi like phenotype (PWP) and one with
XYY. Age effects were examined between parti-
cipants with a secondary medical diagnoses and
participants without a secondary medical diagnoses
using Mann–Whitney U-test, and there was no
significant group difference (Z¼1.24, P¼ 0.21).
In the FXS alone group, 6 (18.2%) subjects
had secondary medical diagnoses and in the FXSþ
ASD group, 22 (38.6%) had secondary medical
diagnoses (Table II). Systematic comparisons bet-
ween the two groups, FXSþASD and FXS alone,
showed a significant difference (Chi squared¼
4.064, df¼ 1, P¼ 0.04). These results indicate that
the group with FXSþASD had approximately twice
as many medical problems that affect the CNS than
the group with FXS alone (Table II). Age effects
were also examined in relation to secondary medical
diagnoses within the FXS alone group and the
FXSþASD group using Mann–Whitney U-test.
There were no significant group differences in age
between individuals with a secondary medical
diagnoses and individuals without a secondary
medical diagnoses in the FXS alone group (Z¼
0.841, P¼ 0.40) or in the FXSþASD group
(Z¼0.730, P¼ 0.47).
Considering seizures only, the FXS alone group
had 4 (12.1%) subjects who had seizures and the
FXSþASD group had 16 (28.1%) subjects who had
seizures; although more than twice as many had
seizures in the FXSþASD group, this difference was
not significant (P¼ 0.15, Table II).
DISCUSSION
Autism occurs in approximately 30% of young
males with FXS, but why autism occurs in only this
subgroup of patients with FXS is not known. This
study demonstrates a higher rate of secondary
medical problems in those with FXSþASD com-
pared with FXS alone. In addition, we found a
significantly lower IQ in those with FXSþASD
compared to FXS alone. These results suggest that
additional brain dysfunction related to secondary
medical diagnoses that affect the CNS can increase
the risk for autism for those with FXS. This could
be associated simply to more general damage to
the brain which could lower IQ or to a secondary
medical diagnosis that specifically relates to gene
dysregulation, that is, PWP. These results are
consistent with the findings of several studies show-
ing lower IQ in those with FXS with autism or ASD
compared to those with FXS alone [Rogers et al.,
2001; Bailey et al., 2001a; Kaufmann et al., 2004;
Loesch et al., 2007]. A number of genetic disorders
can lead to autism without FXS including sex
chromosome abnormalities, 15q duplication, PKU,
and a marker X chromosome [Cohen et al., 2005;
Schaefer and Lutz, 2006]. Genetic disorders can be
documented in 15–40% of patients with autism with
a careful assessment including cytogenetic studies
with FISH testing and metabolic studies [Reddy,
2005; Schaefer and Lutz, 2006].
Seizures
Themost prevalent secondarymedical diagnosis in
FXS is seizures, which was first reported by Lubs in
[1969]. Other studies have described seizures in FXS
and the rate varies between 10% and 40% [Musumeci
et al., 1999; Sabaratnam et al., 2001; Berry-Kravis,
2002]. Rates of seizures are increased in the general
population with developmental disability, thus FXS
is not unique in this regard. We found seizures by
medical history in 22.2% of the subjects overall,
including 12.1% in FXS alone and 28.1% in
FXSþASD. It is also possible that occult EEG
abnormalities occurred more frequently in those
with FXSþASD, but that was not evaluated here.
Seizures can occur in 18–29% in those with autism
without FXS [Olsson et al., 1988; Rapin and Katzman,
1998]. The underlying neuronal abnormalities lead-
ing to neuronal excitability and susceptibility to
seizures may be associated with the development of
autism in those with FXS. In some cases, prolonged
seizures may cause CNS tissue damage which may
predispose to autism. The electrical abnormalities
associated with seizures may also disrupt connecti-
vity in the brain, which may also predispose
individuals with FXS and seizures to autism [Bel-
monte and Bourgeron, 2006]. If further studies
confirm the association between seizures and
autism, this would suggest that treating seizure
activity in young children with FXS may decrease
their risk of having an ASD. In addition, some genes
associated with autism may also predispose to
seizures such as the ARX gene [Nowicki et al.,
2008]. Recently, a mutation in the gene encoding the
contactin-associated protein-like 2 (CASPR2) was
identified as being associated with childhood onset
epilepsy and autism in a sample of Old Order Amish
children [Strauss et al., 2006].
Genetic Disorders
The next most prevalent secondary medical problem,
in our sample of males with FXS, was genetic disorders.
Prader–Willi syndrome (PWS) is a genetic disorder with
a 15q deletion and a phenotype that includes severe
hyperphagia, significant obesity, hypogonadism, and
growth hormone deficiency, demonstrating hypotha-
lamic dysfunction. The Prader–Willi phenotype (PWP)
in FXS is not due to a 15q deletion, but consists of
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obesity, hyperphagia,hypotonia, andoftenhypogonad-
ism [de Vries et al., 1993; de Vries and Niermeijer, 1994;
Nowicki et al., 2007]. The PWP was seen in four patients
described here, all with ASD, and we consider this an
additional genetic abnormalitybecauseadecrease in the
expression of cytoplasmic interacting FMR1 protein
(CYFIP) has been seen in boys with FXS and PWP
[Nowicki et al., 2007]. The gene for CYFIP is located at
15q [Chai et al., 2003]. Patients with PWP do not have
short stature, as seen in PWS, but hyperphagia and
obesity are present and approximately 50% have small
genitaliaordelayedpuberty as reported inNowicki et al.
[2007].
We found a low rate of secondary cytogenetic
abnormalities, with just one patient with XYY
syndrome; although cytogenetic studies were not
routinely carried out in our patients. The association
of sex chromosome abnormalities with FXS has been
reported in the past, primarily FXS with XXY
[Chudley, 1990; Kupke et al., 1991; Milunsky et al.,
1993]. Two cases of 46,XY and 47,XYY mosaicism in
association with FXS have been reported [Bodurtha
et al., 1993; Milunsky et al., 1993]. Although there
have been some reports of autism in males with XYY
syndrome [Nicolson et al., 1998; Geerts et al., 2003],
ASD was not seen in our case of XYYþ FXS.
This study suggests that secondary medical dia-
gnoses that affect the CNS should be examined
in patients with FXS and autism or ASD. These
abnormalities may occur silently and include differ-
ences in gene expression, such as CYFIP expression
in patients with FXS and the PWP. Another example
of gene expression changes in autism is the low
expression of MeCP2 in the brains of individuals
diagnosed with autism but without Rett Syndrome or
fragile X. Although the MeCP2 protein regulates
the FMR1 gene expression, we do not know the
expression of MeCP2 in the brains of individuals with
FXS, either with our without autism.
Ourfindings are consistentwith thehypothesis that
children with FXS and ASD are more likely to have
a secondary medical problem compared to those
with FXS alone. It is important to note that there may
have been a sample bias since it is probable that
more of the FXSþASD participants who were
more severe in presentation to their doctors might
have been more likely to be referred for evaluation
of the secondary medical diagnoses, that is, EEG
studies. In other words, it is probable that not every
participant was equally screened for a secondary
medical diagnosis. Our research suggests that
clinicians should be careful to rule out seizures or
EEG abnormalities in individuals with FXSþASD.
Treatment with an anticonvulsant in those with
seizures may help subsequent social development
in those with autism with or without FXS. Although
additional genetic problems such as Down syn-
drome or the Prader–Willi phenotype are recogniz-
able by their physical phenotype, some may involve
occult expression abnormalities of genes such as
MeCP2, CYFIP, or other yet unidentified genes. The
search for additional gene dysregulation associated
with autism in FXS may also be pertinent to
individuals with autism of unknown etiology.
ACKNOWLEDGMENTS
This study was partially supported by NICHD
HD36071 and HD02274, and the NIH Pediatric
Research LRP for Dr. Tartaglia. We would also like
to thank the M.I.N.D. Institute and Dr. Josep Artigas
for providing the opportunity for Catalina Garcia
Nonell and Eugenia Rigau Ratera to study at the
M.I.N.D. Institute.
REFERENCES
APA. 1994. Diagnostic and Statistical Manual of Mental Disorders,
4th edition. Washington DC: American Psychiatric Associa-
tion.
Artigas J, Brun C. 2004. Se peude atribuir el fenotipo conductual
del sindrome X fragil al retraso mental y al trastorno por deficit
de atencion/hiperactividad? Rev Neurol 38:7–11.
Bailey DB Jr, Hatton DD, Skinner M, Mesibov GB. 2001a. Autistic
behavior, FMR1 protein, and developmental trajectories in
young males with fragile X syndrome. J Autism Dev Disord 31:
165–174.
Bailey DB Jr, Hatton DD, Tassone F, Skinner M, Taylor AK. 2001b.
Variability in FMRP and early development in males with
fragile X syndrome. Am J Ment Retard 106:16–27.
Belmonte MK, Bourgeron T. 2006. Fragile X syndrome and autism
at the intersection of genetic and neural networks. Nat
Neurosci 9:1221–1225.
Berry-Kravis E. 2002. Epilepsy in fragile X syndrome. Dev Med
Child Neurol 44:724–728.
Bodurtha J, Jackson Cook C, Maddalena A, Piserchio J, Waller R.
1993. 46XY/47XYY mosaicism and fragile X [letter]. Clin Genet
44:109–110.
Brown WT, Jenkins EC, Friedman E, Brooks J, Wisniewski K,
Raguthu S, French J. 1982. Autism is associated with the
fragile-X syndrome. J Autism Dev Disord 12:303–308.
Chai JH, Locke DP, Greally JM, Knoll JH, Ohta T, Dunai J, Yavor A,
Eichler EE, Nicholls RD. 2003. Identification of four highly
conserved genes between breakpoint hotspots BP1 and BP2
of the Prader-Willi/Angelman syndromes deletion region that
have undergone evolutionary transposition mediated by
flanking duplicons. Am J Hum Genet 73:898–925.
Chudley AE. 1990. Sex chromosomal and autosomal aneuploidy
in the fragile X syndrome. Birth Defects Orig Artic Ser 26:257–
265.
Cohen D, Pichard N, Tordjman S, Baumann C, Burglen L,
Excoffier E, Lazar G, Mazet P, Pinquier C, Verloes A, Heron D.
2005. Specific genetic disorders and autism: Clinical contri-
bution towards their identification. J Autism Dev Disord 35:
103–116.
de Vries BB, Niermeijer MF. 1994. The Prader-Willi-like pheno-
type in fragile X patients: A designation facilitating
clinical (and molecular) differential diagnosis. J Med Genet
31:820.
de Vries BB, Fryns JP, Butler MG, Canziani F, Wesby-van Swaay E,
van Hemel JO, Oostra BA, Halley DJJ, Niermeyer MF. 1993.
Clinical and molecular studies in fragile X patients with a
Prader-Willi-like phenotype. J Med Genet 30:761–766.
Estecio M, Fett-Conte AC, Varella-Garcia M, Fridman C, Silva AE.
2002. Molecular and cytogenetic analyses on Brazilian youths
with pervasive developmental disorders. J Autism Dev Disord
32:35–341.
SECONDARY MEDICAL DIAGNOSES IN FRAGILE X 1915
American Journal of Medical Genetics Part A
Geerts M, Steyaert J, Fryns JP. 2003. The XYY syndrome: A follow-
up study on 38 boys. Genet Couns 14:267–279.
Hagerman RJ. 2002. Physical and behavioral phenotype. In:
Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome:
Diagnosis, treatment and research 3rd edition. Baltimore: The
Johns Hopkins University Press. p 3–109.
Harris SW, Goodlin-Jones B, Nowicki ST, Hessl D, Tassone F,
Barabato I, Ferranti J, Rogers S, Hagerman RJ. 2008. Autism
Profiles of Young Males with Fragile X Syndrome. Am J Med
Genet Part A (in press).
Hatton D, Sideris J, Skinner M, Mankowski J, Bailey DB Jr, Roberts
J, Mirrett P. 2006. Autistic behavior in children with fragile
X syndrome: Prevalence, stability, and the impact of FMRP.
Am J Med Genet Part A 140A:1804–1813.
Kaufmann WE, Cortell R, Kau AS, Bukelis I, Tierney E, Gray RM,
Cox C, Capone GT, Stanard P. 2004. Autism spectrum disorder
in fragile X syndrome: Communication, social interaction,
and specific behaviors. Am J Med Genet Part A 129A:225–
234.
Kittler P, Krinsky-McHale SJ, Devenny DA. 2004. Sex differences
in performance over 7 years on the Wechsler Intelligence
Scale for Children—Revised among adults with intellectual
disability. J Intellect Disabil Res 48:114–122.
Kupke KG, Soreng AL, Muller U. 1991. Origin of the super-
numerary X chromosome in a patient with fragile X and
Klinefelter syndrome. Am J Med Genet 38:440–444.
Lachiewicz AM, Dawson DV, Spiridigliozzi GA. 2000. Physical
characteristics of young boys with fragile X syndrome:
Reasons for difficulties in making a diagnosis in young males.
Am J Med Genet 92:229–236.
Loesch DZ, Bui QM, Dissanayake C, Clifford S, Gould E, Bulhak-
Paterson D, Tassone F, Taylor AK, Hessl D, Hagerman R,
Huggins RM. 2007. Molecular and cognitive predictors of the
continuum of autistic behaviours in fragile X. Neurosci
Biobehav Rev 31:315–326.
Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore
PC, Pickles A, Rutter M. 2000. The Autism Diagnostic
Observation Schedule-Generic: A standard measure of social
and communication deficits associated with the spectrum of
autism. J Autism Dev Disord 30:205–223.
Lubs HA. 1969. A marker X chromosome. Am J Hum Genet
21:231–244.
Milunsky A, Huang X, Amos JA, Herskowitz J, Farrer LA, Wyandt
HE. 1993. 46: XY/47,XYY male with the fragile X syndrome:
Cytogenetic and molecular studies. Am J Med Genet 45:589–
593.
Musumeci SA, Hagerman RJ, Ferri R, Bosco P, Dalla Bernardina B,
Tassinari CA, De Sarro GB, Elia M. 1999. Epilepsy and EEG
findings in males with fragile X syndrome. Epilepsia 40:1092–
1099.
Nicolson R, Bhalerao S, Sloman L. 1998. 47: XYY karyotypes and
pervasive developmental disorders. Can J Psychiatry 43:619–
622.
Nolin SL, Lewis FA III, Ye LL, Houck GE Jr, Glicksman AE,
Limprasert P, Li SY, Zhong N, Ashley AE, Feingold E, Sherman
SL, Brown WT. 1996. Familial transmission of the FMR1 CGG
repeat. Am J Hum Genet 59:1252–1261.
Nowicki ST, Tassone F, Ono MY, Ferranti J, Croquette MF,
Goodlin-Jones B, Hagerman RJ. 2007. The Prader-Willi
phenotype of fragile X syndrome. J Dev Behav Pediatr 28:
133–138.
Nowicki ST, Hansen RL, Hagerman RJ. 2008. X-linked intellectual
disabilities. In: Accardo PJ, editor. Neurodevelopmental
Disabilities in Infancy and Childhood (Third Edition): The
Spectrum of Neurodevelopmental Disbilities (Volume 2).
Baltimore: Paul H. Brookes Publishing Co. p 331–351.
Olsson I, Steffenburg S, Gillberg C. 1988. Epilepsy in autism and
autistic-like conditions. A population-based study. Arch
Neurol 45:666–668.
Philofsky A, Hepburn SL, Hayes A, Hagerman RJ, Rogers SJ. 2004.
Linguistic and cognitive functioning and autism symptoms in
young children with fragile X syndrome. Am J Ment Retard
109:208–218.
Rapin I, Katzman R. 1998. Neurobiology of autism. Ann Neurol
43:7–14.
Reddy KS. 2005. Cytogenetic abnormalities and fragile-X
syndrome in Autism Spectrum Disorder. BMC Med Genet 6:3.
Riddle JE, Cheema A, Sobesky WE, Gardner SC, Taylor AK,
Pennington BF, Hagerman RJ. 1998. Phenotypic involvement
in females with the FMR1 gene mutation. Am J Ment Retard
102:590–601.
Rogers SJ, Wehner EA, Hagerman RJ. 2001. The behavioral
phenotype in Fragile X: Symptoms of autism in very young
children with Fragile X syndrome, idiopathic autism, and
other developmental disorders. J Dev Behav Pediatr 22:409–
417.
Roid GH, Miller LJ. 1997. Leiter International Performance Scale-
Revised. Lutz: Psychological Assessment Resources, Inc.
Sabaratnam M, Vroegop PG, Gangadharan SK. 2001. Epilepsy
and EEG findings in 18 males with fragile X syndrome. Seizure
10:60–63.
Saluto A, Brussino A, Tassone F, Pappi P, Arduino C, Hagerman
PJ, Migone N, Brusco A. 2005. An enhanced polymerase chain
reaction assay to detect pre- and full mutation alleles of the
fragile X mental retardation 1 gene. J Mol Diagn 7:605–612.
SchaeferGB, Lutz RE. 2006. Diagnostic yield in the clinical genetic
evaluation of autism spectrum disorders. Genet Med 8:549–
556.
Sherman S. 2002. Epidemiology. In: Hagerman RJ, Hagerman PJ,
editors. Fragile X syndrome: Diagnosis, treatment and
research. 3rd edition. Baltimore: The Johns Hopkins Univer-
sity Press. p 136–168.
Sparrow SS, Balla DA, Cicchetti DV. 1984. Vineland adaptive
behavior scales survey form manual. Circle Pines: American
Guidance Service.
Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin
SE, Parod JM, Stephan DA, Morton DH. 2006. Recessive
symptomatic focal epilepsy and mutant contactin-associated
protein-like 2. N Engl J Med 354:1370–1377.
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